uniQure N.V. Foreign Currency Transaction Gain, before Tax
uniQure N.V. (QURE) reported Foreign Currency Transaction Gain, before Tax of $900.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-28.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:ForeignCurrencyTransactionGainBeforeTax · last filed 2019-02-28
- uniQure N.V. foreign currency transaction gain, before tax for the quarter ending 2018-03-31 was $600.00K.
- uniQure N.V. foreign currency transaction gain, before tax for the quarter ending 2017-12-31 was $300.00K.
- uniQure N.V. foreign currency transaction gain, before tax for the quarter ending 2017-09-30 was $700.00K.
- uniQure N.V. foreign currency transaction gain, before tax for the quarter ending 2017-06-30 was $1.30M.
- uniQure N.V. foreign currency transaction gain, before tax for fiscal 2018 was $900.00K, a 65.38% decline from fiscal 2017.
- uniQure N.V. foreign currency transaction gain, before tax for fiscal 2017 was $2.60M, a 188.89% increase from fiscal 2016.
- uniQure N.V. foreign currency transaction gain, before tax for fiscal 2016 was $900.00K, a 59.09% decline from fiscal 2015.
- uniQure N.V. foreign currency transaction gain, before tax for fiscal 2015 was $2.20M.
| Period end | Foreign Currency Transaction Gain, before Tax 3 month | Foreign Currency Transaction Gain, before Tax 6 month | Foreign Currency Transaction Gain, before Tax 9 month | Foreign Currency Transaction Gain, before Tax 12 month |
|---|---|---|---|---|
| 2018-12-31 | $900.00K 10-K · filed 2019-02-28 | |||
| 2018-03-31 | $600.00K 10-Q · filed 2018-04-30 | $900.00K derived: sum of 2 quarters · filed 2019-02-28 | $1.60M derived: sum of 3 quarters · filed 2019-02-28 | $2.90M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $1.00M derived: sum of 2 quarters · filed 2019-02-28 | $2.30M derived: sum of 3 quarters · filed 2019-02-28 | $2.60M 10-K · filed 2019-02-28 |
| 2017-09-30 | $700.00K 10-Q · filed 2018-11-06 | $2.00M derived: sum of 2 quarters · filed 2018-11-06 | $2.30M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $1.30M 10-Q · filed 2018-08-08 | $1.60M 10-Q · filed 2018-08-08 | ||
| 2016-12-31 | $900.00K 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $2.20M 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |